A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects with Active Psoriatic Arthritis
Phase of Trial: Phase II
Latest Information Update: 16 Nov 2018
At a glance
- Drugs Tildrakizumab (Primary)
- Indications Psoriatic arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sun Pharma Global FZE
- 31 Aug 2018 Biomarkers information updated
- 16 Feb 2018 Planned End Date changed from 1 Sep 2019 to 15 May 2020.
- 16 Feb 2018 Planned primary completion date changed from 1 Sep 2019 to 15 Jan 2020.